Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

All articles

Showing 301–312 of 411 articles

  • Interpret the evidence

    What a Rat Navigation Study Can Tell Us About Pinealon and Learning

    Pinealon, also called EDR, is a three-amino-acid peptide. An older study examined how young and old rats performed on a navigation task after exposure to Pinealon or a different preparation.

    Pinealon1 source (2013)

  • Check methods and identity

    Why Biological Age Measures Do Not Establish That Pinealon Extends Life

    Pinealon is a three-amino-acid peptide also known as EDR. An older human report examined Pinealon and another peptide preparation, Vesugen, in people with several chronic conditions. It is useful for understanding what the researchers meant by biological age.

    Pinealon1 source (2015)

  • Check methods and identity

    What the Current US Bremelanotide Label Covers

    PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication.

    PT-1411 source (2026)

  • Check methods and identity

    How Two Phase 3 Trials Measured Desire and Distress Separately

    Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Two older phase 3 studies directly tested the prescription candidate in premenopausal women with hypoactive sexual desire disorder. The 2026 label still summarizes these pivotal comparisons.

    PT-1412 sources (2019, 2026)

  • Check methods and identity

    What the 2026 Bremelanotide Label Reports About Safety

    PT-141 is also known as bremelanotide. The October 2026 US label for the approved product, Vyleesi, records safety findings from its clinical evaluation. Those findings apply to that specific drug product and the settings in which it was studied.

    PT-1411 source (2026)

  • Understand the science

    What a Receptor Structure Can Explain About PT-141

    Bremelanotide, also called PT-141, is a cyclic peptide in the melanocortin research family. The current US label describes it as a melanocortin receptor agonist.

    PT-1412 sources (2021, 2026)

  • Explore study findings

    What Participants Reported After the Bremelanotide Trials

    Bremelanotide, also called PT-141, was evaluated in the RECONNECT trials for hypoactive sexual desire disorder. An older exit-study report examined what some trial participants said about their experience.

    PT-1412 sources (2021, 2026)

  • Interpret the evidence

    Why the Bremelanotide Extension Study Cannot Replace a Placebo Comparison

    PT-141, or bremelanotide, had a 52-week extension after the controlled phase of the RECONNECT studies. The older extension is the direct source for this comparison of study designs. Its results should be read alongside the current US labeling.

    PT-1412 sources (2019, 2026)

  • Understand the science

    How two retatrutide trials counted breathing interruptions during sleep

    Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. “RETA GLP-3” is a catalog label. Its number does not name a receptor target. A 2026 report examined retatrutide in adults with moderate to severe obstructive sleep apnea.

    RETA GLP-33 sources (2025, 2026)

  • Explore study findings

    What TRIUMPH-1 established about average weight change

    Retatrutide activates the GIP, GLP-1 and glucagon receptors, the three targets behind its description as a triple agonist. The “GLP-3” catalog wording refers to the entry, while the scientific names identify the receptors studied.

    RETA GLP-32 sources (2025, 2026)

  • Explore study findings

    Why TRIUMPH-2 enrolled adults with type 2 diabetes

    Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. “GLP-3” is catalog wording for this triple agonist. The 2026 TRIUMPH-2 report asked what happened to body weight in participants who had both type 2 diabetes and excess body weight.

    RETA GLP-32 sources (2026)

  • Check methods and identity

    What a three-sample retatrutide analysis showed about labeling

    Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” wording is a catalog label. A 2026 Australian paper examined a different question from the clinical trials.

    RETA GLP-32 sources (2026)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)